Search
Displaying 411–420 of 689 for “retinitis clinical trial”
-
Full Transcript - 2019 Investing in Cures Summit - March 2, 2019
Full Session Transcripts of the 2019 Investing in Cures Summit.
-
Foundation Summit Highlights Robust Growth in Commercial Development for Retinal Disease Therapies
Foundation NewsThe Foundation’s Investing in Cures Summit (ICS), held on April 2, 2022, in Half Moon Bay, California, convened 175 researchers, industry executives, and constituents to present and discuss the expanding and accelerating commercial development of emerging therapies for retinal degenerative diseases.
-
Proceed with Caution as Cell-Based Retinal Disease Therapies Show Promise.
In recent years, the number of stem cell treatments offered by various clinics claiming to benefit retinal eye disease has increased. Of concern, are those clinics administering stem cell-based therapies that do not adhere to the U.S. Food and Drug Administration’s (FDA) standards. Recently, a federal court ruled that the FDA has regulatory authority over stem cell procedures and has the power to halt them, even if the stem cells originate from the participating patient.
-
Virtual Workshop on Inflammation in Viral Gene Therapy of the Retina
This workshop was designed to bring together industry and academia to discuss openly what is known about the interactions of viral-mediated gene therapy of the retina with the immune system and the clinical consequences of that.
-
The Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for blinding retinal diseases, is hosts webinars to inform eye care professionals about the many opportunities to greatly enhance the quality of life, and provide hope, for their retinal disease patients.
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2021 (July 1, 2020–June 30, 2021)
-
Pediatric Ophthalmologists Target Inherited Retinal Diseases
In the PressNew opportunities continue to develop in an evolving landscape.
-
A Retinal Research Nonprofit Paves the Way for Commercializing Gene Therapies
In the PressAN EMERGING, vision-restoring gene therapy for a devastating retinal disease is poised for Food and Drug Administration (FDA) approval. If it gets the regulatory nod, it will be the first gene therapy to receive FDA approval for the eye or an inherited condition.
-
Investing in Cures Summit 2021
The 2021 Investing in Cures Summit (ICS) convenes key stakeholders of the Foundation Fighting Blindness and RD Fund to learn from the world’s leading industry, clinical and retinal science innovators poised to take emerging therapies across the finish line.
